T37.93XA
✓ BillablePoisoning by unspecified systemic anti-infective and antiparasitics, assault, initial encounter
Injury, poisoning and certain other consequences of external causes (S00-T88)
❌ Excludes1
inheritedRules inherited from parent codes in the hierarchy.
- • anti-infectives topically used for ear, nose and throat (T49.6-)
- • anti-infectives topically used for eye (T49.5-)
- • locally applied anti-infectives NEC (T49.0-)
Clinical Description
ICD-10-CM code T37.93XA represents poisoning by unspecified systemic anti-infective and antiparasitics, assault, initial encounter. This code falls under the Injury, poisoning and certain other consequences of external causes (S00-T88) classification. It is a billable/specific code valid for HIPAA-covered transactions as of October 1, 2025 (FY2026). This code can be used to indicate a diagnosis for reimbursement purposes on insurance claims.
This is a 8-character code at the 7th level of specificity. This is the most specific code available in this subcategory. Coders should note that T37.93XA has 3 Excludes1 restriction(s) — codes that cannot be reported together on the same claim.
Frequently Asked Questions
What is ICD-10 code T37.93XA?
ICD-10-CM code T37.93XA is "Poisoning by unspecified systemic anti-infective and antiparasitics, assault, initial encounter". It belongs to the category: Injury, poisoning and certain other consequences of external causes (S00-T88).
Is T37.93XA a billable ICD-10 code?
Yes, T37.93XA is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
What codes are excluded with T37.93XA?
T37.93XA has 3 Excludes1 rule(s). These codes are mutually exclusive and cannot be coded together on the same claim.
Related Codes in T37.93
Other codes in the same category that may be relevant for differential coding:
🧪 Validate Combinations
Add T37.93XA to the Excludes Checker to validate against your full code list.
Open in Checker →Code Information
Data Source
CMS ICD-10-CM 2026 Tabular List
Updated October 1, 2025 (FY2026)